 Connection
Catherine Derington to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Catherine Derington has written about Angiotensin-Converting Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.782 |
|
|
|
-
Derington CG, Berchie RO, Scharfstein DO, Andrews RM, Greene TH, Xu Y, King JB, Supiano MA, Sonnen JA, Williamson J, Pajewski NM, Pruzin JJ, Cohen JB, Bress AP. Effect of Initiation and Continuous Adherence to ARBs Versus ACEIs on Risk of Adjudicated Mild Cognitive Impairment or Dementia. J Gerontol A Biol Sci Med Sci. 2025 Jun 10; 80(7).
Score: 0.862
-
Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One. 2021; 16(4):e0248080.
Score: 0.647
-
Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King JB. Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension. 2023 03; 80(3):590-597.
Score: 0.181
-
King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen JB. New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. J Am Heart Assoc. 2023 09 05; 12(17):e030311.
Score: 0.048
-
Cohen JB, Marcum ZA, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Scharfstein D, Williamson J, Pajewski NM, Bress AP. Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Netw Open. 2022 07 01; 5(7):e2220680.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|